(Alliance News) - AstraZeneca PLC on Tuesday said it has simplified its contract with Sanofi SA and Swedish Orphan Biovitrum, or Sobi, relating to the development and commercialisation of nirsevimab in the US, while Sanofi has also refiled its premerger form for its acquisition of Provention Bio Inc. Read More
(Alliance News) - Stocks in London are called to open higher on Tuesday, with European markets expected to begin the abbreviated week strongly following the long Easter weekend. Read More
(Alliance News) - Stocks in London closed higher on Thursday, ahead of the long Easter weekend, defying gloomy local data as well as increasing expectations of a global economic slowdown. Read More
(Alliance News) - Stock prices in London opened higher on Thursday, but sentiment was fragile amid fears of an economic slowdown in the US, and heightened geopolitical tensions. Read More
(Alliance News) - The NHS has approved the use of a drug by AstraZeneca PLC which could benefit hundreds of patients with breast cancer and prostate cancer. Read More
(Alliance News) - Stocks in London closed largely lower on Wednesday, while the FTSE 100 ended in the green thanks to a solid performance from utility and pharmaceutical stocks. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said it has received positive results from interim analysis of the DUO-O phase 3 trial of its Imfinzi drug. Read More
(Alliance News) - AstraZeneca PLC on Monday said the EU's Committee for Medicinal Products for Human Use of the European Medicine Agency recommended the approval of ultomiris for the treatment of adult patients with a form of neuromyelitis optica spectrum disorder. Read More
(Alliance News) - AstraZeneca PLC on Thursday said it has completed an exclusive global license agreement with KYM Biosciences Inc for its CMG901 treatment. Read More
(Alliance News) - Stocks in London are set to build on Wednesday's gains, as risk appetite recovers following the recent banking turmoil. Read More
(Alliance News) - AstraZeneca PLC on Monday announced positive high-level results from its Neuro-TTRansform phase III trial for eplontersen, while Enhertu received another approval in Japan. Read More
(Alliance News) - Stocks in London were called to open higher on Monday, as investors look past the recent turbulence in the banking sector. Read More
(Alliance News) - AstraZeneca PLC on Thursday said its drug Calquence received its first approval in China, for adults with previously treated mantle cell lymphoma, a rare type of non-Hodgkin lymphoma. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday: Read More
(Alliance News) - AstraZeneca PLC on Thursday hailed phase 3 trial results on its lung cancer drugs Imfinzi and Tagrisso. Read More
(Alliance News) - AstraZeneca PLC on Monday hailed phase 2 trial results of its cancer drug Enhertu, which it develops with Daiichi Sankyo Co Ltd. Read More
(Alliance News) - Stocks in London were called to open flat on Monday, as the dollar softened ahead of a consequential week for US economic data and monetary policy guidance. Read More
(Alliance News) - AstraZeneca PLC and Merck & Co Inc said on Thursday that the US Food & Drug Administration will convene a meeting of the Oncologic Drugs Advisory Committee to discuss the supplemental new drug application for Lynparza in combination with abiraterone and prednisone or prednisolone. Read More
AstraZeneca PLC - Cambridge, UK-based pharmaceuticals firm - Announces wholly owned subsidiary AstraZeneca Finance prices a three tranche global bond offering totalling USD2.25 billion on February 28. Expects offering to close on March 3. Says the notes issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by AstraZeneca are USD1.1 billion of fixed rate notes with a coupon of 4.875%, maturing March 3 2028, USD650 million of fixed rate notes with a coupon of 4.900%, maturing March 3 2030, and USD500 million of fixed rate notes with a coupon of 4.875%, maturing March 3, 2033. Expects to use the net proceeds of the offering for general corporate purposes, which may include the refinancing of existing indebtedness. Read More